Episode Details

Despite a massive $276M net loss, Elanco’s Q4 2025 earnings sent the stock surging 9% as the market priced in record innovation revenues over a legacy accounting cleanup.

In ~10 minutes:

- Why a nameless $47M impairment is hiding in the restructuring math.

- The 16.2% "phantom interest" charge severely skewing the balance sheet.

- How an aggressive product bundling strategy is boxing out competitors.

- Why your vet bill is seeing a five-year record price hike.

Elanco is currently walking a tightrope, offsetting an enormous $202M quarterly cleanup charge with sheer top-line momentum from its core vet blockbusters. But with low-margin farm volumes pulling down gross profits and federal agriculture subsidies freezing, management is cleverly lowballing 2026 guidance to give themselves a built-in cushion for the second half of the year.

Elanco Animal Health Incorporated (ELAN) | Q4 FY2025

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.